70
Participants
Start Date
April 4, 2022
Primary Completion Date
November 13, 2024
Study Completion Date
November 13, 2024
Mim8
"For treatment part 1, all participants will start on once-weekly treatment and continue on this regimen until week 26. For treatment part 2, starting at week 26, all participants will be offered the choice to remain on once-weekly or switch to once-monthly dosing.~Mim8 will be injected with a thin needle into the skin"
NTU Hospital - Children and Women Hospital, Taipei
Charlotte Maxeke Johannesburg Academic Hospital, Parktown, Johannesburg
Pädiatrische Onkologie-Hämatologie, Lucerne
St Christopher Hosp for Child, Philadelphia
Daejeon Eulji Medical Center, Eulji University, Daejeon
Univ Hosp Cleveland Med Ctr, Cleveland
University of Iowa_Iowa City, Iowa City
Sheba MC The Israeli National Hemophilia Center, Tel Litwinsky
Beijing Children's Hospital，Capital Medical University, Beijing
Post Graduate Institute of Child Health, Noida
Institute of hematology and Blood Diseases Hospital, Tianjin-Hematology, Tianjin
J K Lon Hospital, Jaipur
Children's Hospital, Zhejiang University school of medicine, Hangzhou
Seth GS Medical College & KEM Hospital, Mumbai
Sahyadri Super Speciality Hospital, Pune
Haemotology, Nanfang Hospital, Southern Medical University, Guangzhou
Chengdu Women's and Children's central hospital, Chengdu
Penn State MS Hershey Med Ctr, Hershey
The Hospital for Sick Children, Toronto
Ospedale Pediatrico Bambino Ges, Rome
Ota Memorial Hospital_Pediatrics, Gunma
Academisch Medisch Centrum, Amsterdam
Uniwersytecki Szpital Kliniczny im. J.Mikulicza-Radeckiego, Wroclaw
Uniwersytecki Szpital Dzieciecy, Dzial Krwiolecznictwa, Lublin
Centro Hospitalar Lisboa Central - Hospital Dona Estefânia, Lisbon
Severance Hospital, Yonsei University Health System, Seoul
Hospital Sant Joan de Déu, Esplugues Llobregat
Arthur Bloom Haemophilia Centre, Cardiff
St Thomas' Hospital, London
Lead Sponsor
Novo Nordisk A/S
INDUSTRY